Catalog No.
PHG55501
Species reactivity
Human
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
E. coli - derived recombinant Human BIRC3 (Thr254-Asp419).
Tested applications
ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000
Target
hIAP1, RING finger protein 49, IAP homolog C, RING-type E3 ubiquitin transferase BIRC3, MIHC, Cellular inhibitor of apoptosis 2, API2, C-IAP2, RNF49, BIRC3, Apoptosis inhibitor 2, TNFR2-TRAF-signaling complex protein 1, Baculoviral IAP repeat-containing protein 3, Inhibitor of apoptosis protein 1, hIAP-1
Purification
Purified by antigen affinity column.
Accession
Q13489
Applications
ELISA, IHC, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Selective disruption of Traf1/cIAP2 interaction attenuates inflammatory responses and rheumatoid arthritis., PMID:39913998
Chronic Lymphocytic Leukemia IGHV Somatic Hypermutation Detection by Targeted Capture Next-Generation Sequencing., PMID:38175592
Anti-complement 5 antibody ameliorates antibody-mediated rejection after liver transplantation in rats., PMID:37398677
Clinical relevance of molecular aspects in extranodal marginal zone lymphoma: a critical appraisal., PMID:37389189
Targeting cIAPs attenuates CCl4-induced liver fibrosis by increasing MMP9 expression derived from neutrophils., PMID:34914932
Kaempferol sensitizes tumor necrosis factor-related apoptosis-inducing ligand-resistance chronic myelogenous leukemia cells to apoptosis., PMID:34820749
Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma., PMID:34797699
BET Inhibition Enhances TNF-Mediated Antitumor Immunity., PMID:34782346
Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM)., PMID:34506616
Perspectives on Precision Medicine in Chronic Lymphocytic Leukemia: Targeting Recurrent Mutations-NOTCH1, SF3B1, MYD88, BIRC3., PMID:34442029
Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study., PMID:32986498
Targeted next-generation sequencing reveals molecular heterogeneity in non-chronic lymphocytic leukemia clonal B-cell lymphocytosis., PMID:32738175
Chronic lymphocytic leukemia patients with IGH translocations are characterized by a distinct genetic landscape with prognostic implications., PMID:32720348
Response in patients with BIRC3-mutated relapsed/refractory chronic lymphocytic leukemia treated with fixed-duration venetoclax and rituximab., PMID:32611578
Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax., PMID:32206772
Clinical significance of TP53, BIRC3, ATM and MAPK-ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF CLL4 trial., PMID:32015491
Next-generation hypomethylating agent SGI-110 primes acute myeloid leukemia cells to IAP antagonist by activating extrinsic and intrinsic apoptosis pathways., PMID:31831875
Fibroblast growth factor 21 protects against lipotoxicity-induced pancreatic β-cell dysfunction via regulation of AMPK signaling and lipid metabolism., PMID:31654570
Primary Low-Grade B-Cell Lymphoma of Skull With Translocation Between Immunoglobulin and Interferon Regulatory Factor 4 Genes., PMID:31631721
The synergism of Clinacanthus nutans Lindau extracts with gemcitabine: downregulation of anti-apoptotic markers in squamous pancreatic ductal adenocarcinoma., PMID:31521140
Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia., PMID:31371416
Distinct immunoglobulin heavy chain variable region gene repertoire and lower frequency of del(11q) in Taiwanese patients with chronic lymphocytic leukaemia., PMID:31230372
LncRNA HCP5 promotes triple negative breast cancer progression as a ceRNA to regulate BIRC3 by sponging miR-219a-5p., PMID:31215169
Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience., PMID:31054420
Splenic marginal zone lymphomas in acquired C1-inhibitor deficiency: clinical and molecular characterization., PMID:30073422
Normal serum protein electrophoresis and mutated IGHV genes detect very slowly evolving chronic lymphocytic leukemia patients., PMID:29745034
A novel SMAC mimetic APG-1387 exhibits dual antitumor effect on HBV-positive hepatocellular carcinoma with high expression of cIAP2 by inducing apoptosis and enhancing innate anti-tumor immunity., PMID:29679556
Genetic landscape of ultra-stable chronic lymphocytic leukemia patients., PMID:29365086
Alcoholic hepatitis versus non-alcoholic steatohepatitis: Levels of expression of some proteins involved in tumorigenesis., PMID:29307797
Zoledronic acid overcomes chemoresistance by sensitizing cancer stem cells to apoptosis., PMID:29300112
Novel prognostic molecular factors: a quantum leap in the field of chronic lymphocytic leukemia., PMID:28994094
Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL., PMID:28592889
[Chronic lymphocytic leukemia: pathophysiology and current therapy]., PMID:28592762
Whole-genome sequencing of chronic lymphocytic leukaemia reveals distinct differences in the mutational landscape between IgHVmut and IgHVunmut subgroups., PMID:28584254
Differential regulation of cell death pathways by the microenvironment correlates with chemoresistance and survival in leukaemia., PMID:28582465
Identification of a TLR2-regulated gene signature associated with tumor cell growth in gastric cancer., PMID:28481875
Distinct molecular genetics of chronic lymphocytic leukemia in Taiwan: clinical and pathogenetic implications., PMID:28255015
MALT lymphoma: A paradigm of NF-κB dysregulation., PMID:27452667
Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy., PMID:27226433
Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors., PMID:27198719
CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia., PMID:27109509
Targeting Non-proteolytic Protein Ubiquitination for the Treatment of Diffuse Large B Cell Lymphoma., PMID:27070702
Genomic Features: Impact on Pathogenesis and Treatment of Chronic Lymphocytic Leukemia., PMID:26890126
Chronic lymphocytic leukemia (CLL)-Then and now., PMID:26690614
Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations., PMID:26675346
A Low Frequency of Losses in 11q Chromosome Is Associated with Better Outcome and Lower Rate of Genomic Mutations in Patients with Chronic Lymphocytic Leukemia., PMID:26630574
[Molecular Prognostic Markers and Their Clinical Relevance in Chronic Lymphocytic Leukemia]., PMID:26489496
c-IAP ubiquitin protein ligase activity is required for 4-1BB signaling and CD8(+) memory T-cell survival., PMID:26096449
The complex interplay between cell-intrinsic and cell-extrinsic factors driving the evolution of chronic lymphocytic leukemia., PMID:25963298
Mutations in chronic lymphocytic leukemia and how they affect therapy choice: focus on NOTCH1, SF3B1, and TP53., PMID:25696844
For research use only. Not for human or drug use.
